The Central Commission for Discipline Inspection issued a document named medical corruption

With volume procurement crackdown with gold sales article mentioned the recent crown stent belt volume procurement, 11 domestic and foreign enterprises 26 crown vein bracket products to participate in the bidding, through public bidding to produce 10 products to be selected, bracket price from the average price of about 13,000 yuan to about 700 yuan.
comment pointed out that the collection of high-value consumables to reduce product prices is to continue to deepen the reform of the centralized procurement system of pharmaceutical supplies for patients to bring benefits, but also a multi-pronged effort to promote the medical industry, one of the important measures.
, according to Cypress Blue combing, for high-value consumables of the belt procurement in the national organization of drug centralized belt procurement almost carried out to the third batch when the news began to come out.
It is learned that in July 2020, the State Health Insurance Administration issued a letter on entrusting the implementation of the centralized belt procurement program (draft for comments) of the national organization's crown vein bracket, and proposed to take the crown stent as the starting point to explore the centralized belt procurement of high-value consumables of the national organization.
with the results of the proposed selection, it is reported that in January 2021, the crown bracket selected enterprises will fulfill the purchase agreement, the full implementation of the price of the selected products.
The reason why the national organization of mining is to promote the medical industry is an important measure to clean up the air is mainly because, whether for drugs or high-value consumables with volume procurement, through the volume exchange price, volume price linkage and other principles to significantly reduce product prices, and through the principle of volume procurement, to ensure the use of selected products in the public hospital market, to a certain extent to eliminate the need for enterprise gold sales.
Enterprise competition from marketing to products According to relevant media reports, in 2019 323 listed pharmaceutical companies sales costs reached 287.3 billion yuan, and was included in the volume of procurement of drugs, procurement volume in the form of contracts to ensure the purchase of drugs, saving intermediate sales costs.
As early as the second batch of national organizations centralized procurement and use of drugs to answer questions, the pilot office, the joint procurement of relevant person-in-charge said that the procurement is to purify the ecological environment of the industry, promote industrial transformation and upgrading of important measures.
" in the decentralized procurement model, some pharmaceutical companies do not pay attention to product innovation, quality and cost control, over-reliance on sales channels.
in this marketing model, drug salespeodes and medical personnel are at risk of breaking the law.
Center procurement based on the evaluation of quality and efficacy consistency, to promote the return of enterprises to cost and quality competition, enterprise public relations behavior will be greatly reduced, inter-enterprise competition into open and transparent product quality and cost competition, under the surface of the gray operation into fair competition under the sun, fundamentally improve the pharmaceutical industry ecological environment, is conducive to the pharmaceutical industry from marketing-driven to innovation-driven transformation."
Take drug belt procurement, the pharmaceutical Rubik's Cube in a report analysis pointed out that the average price of three rounds of collection gradually increased, the average decline of the third round of collection of 70%, the median of 76%, both higher than the previous two rounds, there are 25 standard prices fell by more than 90%.
third round of collection is expected to save the health insurance fund 27.5 billion yuan, 10 disease areas to save the health insurance fund more than 1 billion yuan.
according to the views of the relevant departments, with the steady development of the head drug enterprise consistency evaluation work, over-conformity evaluation of the three varieties of increasing, the fourth batch, the fifth batch ... Even more varieties included in the scope of national harvesting are high probability events.
addition, the procurement of belt quantities for biological agents such as insulin and Chinese medicine is also under exploration.
, Hebei, Anhui, Fujian, Hubei, Hunan, Guangxi, Qinghai and other provinces have carried out collection of some of the larger drugs for varieties that have not been evaluated consistently.
of the provinces, antibiotics accounted for the highest proportion of provincial-level drug collection, the distribution of diseases in different provinces, the proportion of injectables was the highest.
data also show that, with the promotion of volume procurement, a large number of pharmaceutical companies sales costs fell, the selected and non-selected enterprises sales team and variety pipeline are making corresponding adjustments.
based on international experience, the competition of follow-up generic drug companies will gradually shift from the rebate debate on the marketing side to the variety competition on the research and development side.
suggested that, based on the experience of the U.S. generics market, Chinese generics companies could achieve differentiated competition by layout first generics, high-tech barrier generics, Chinese medicine, innovative drugs, etc.
series of policies directly refers to drug corruption Article pointed out that corruption and corruption in the medical field, has been a strong focus of public reaction - high amounts of money involved, corruption interest chain, a large number of disclosed cases of corruption in the medical field, the collection of drug supplies rebates the highest frequency, resulting in high prices of drugs and medical supplies, medical costs too fast growth, health insurance fund loss and other issues.
discipline inspection and supervision organs at all levels, based on their functional responsibilities, closely follow the risk points and high-risk links of integrity in the medical field, seriously investigate and punish leading cadres and public officials of Party members who violate discipline and law, and resolutely cut off the chain of corrupt interests.
, zhejiang Province, the County Commission for Discipline Inspection has been the county health care system, a number of staff suspected of bribery crimes to open a case review and investigation.
pointed out that the investigation and prosecution of cases played a warning, deterrent role, heavy-handed fight against disciplinary violations in the medical field can not be loose, can not be soft.
, we should also work the system and governance, strengthen the restriction and supervision of the operation of power, and promote the multi-pronged construction of comprehensive governance system.
At present, the national medical and health industry is carrying out special actions in the construction of style, focusing on punishing improper acts such as using their position to facilitate the receipt of red envelopes, cracking down on illegal and illegal acts of collecting kickbacks, and seriously investigating and punishing the illegal marketing practices of pharmaceutical products in medical institutions.
same time, the State Health Insurance Administration issued "guidance on the establishment of a medical price and credit evaluation system", involving pharmaceutical commercial bribery and other 7 kinds of disrelieving pharmaceutical enterprises will be included in the "black list" of disrelieving.
Supreme People's Court and the State Health Insurance Administration signed the Memorandum of Cooperation on the Exchange and Sharing of Information on Commercial Bribery Cases in the Pharmaceutical Field, established a regular notification system, and continuously deepened cooperation in the management of commercial bribery in the pharmaceutical field.
multi-sector linkage, playing a series of combination punches, are aimed at rooting out the pharmaceutical bidding or procurement process in the process of profit transmission, covert operation, false price increases and other outstanding issues.
Finally, the article emphasizes that in order to establish a clean industry environment, on the one hand, we should strengthen the ideological education of medical industry personnel, carry out in-depth education on integrity, tighten the "total switch" of faith awareness, on the other hand, we should also focus on promoting the reform of medical service prices, so that doctors' wisdom, medical technology reflects its due value, so that medical workers' services get a reasonable price level.
。